Jiating Sun
Jia Wang1- 1Guangdong-Hong Kong Joint Laboratory of Emerging Infectious Diseases, Joint Institute of Virology (STU/HKU), Shantou University, Shantou, Guangdong, China
- 2Department of Oncology, First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
- 3State Key Laboratory of Emerging Infectious Diseases, School of Public Health, The University of Hong Kong, Hong Kong, Hong Kong SAR, China
- 4Shanghai Institute of Virology, Shanghai, China
Newcastle disease virus (NDV) has emerged as a promising oncolytic agent in cancer therapy. NDV not only directly lyses tumor cells but also activates the host’s innate and adaptive immune responses, demonstrating potent antitumor activity. However, the efficacy of wild-type NDV is often limited and inconsistent. Advances in genetic engineering have led to the development of a new generation of highly effective and safe recombinant Newcastle disease viruses (rNDVs) by deleting non-essential viral genes or incorporating exogenous functional genes. These genetically engineered NDVs further enhance antitumor activity and optimize the tumor microenvironment by increasing pro-inflammatory cytokine secretion and inducing systemic antitumor immunity. In this review, we summarize the current status of rNDVs, modification strategies, antitumor mechanisms, clinical applications, and combination therapies involving rNDVs. We also discuss the current challenges in utilizing NDV for cancer therapy, including determining the most effective delivery routes, developing strategies to evade neutralizing antibodies, overcoming tumor heterogeneity, and identifying relevant biomarkers.
1 Introduction
Cancers represent one of the most significant public health challenges worldwide. Immunotherapy has demonstrated promising potential in cancer treatment; however, it still faces challenges, including limited response rates, drug resistance, and immune-related adverse events (irAEs) (1, 2). The immunosuppressive tumor microenvironment (TME) constitutes a major barrier to the therapeutic efficacy of immunotherapy. Therefore, developing novel therapeutic modalities that can specifically target tumors while simultaneously reversing the immunosuppressive microenvironment has become an urgent priority and a frontier direction in cancer research.
Oncolytic virus (OV) therapy, a highly promising platform for tumor treatment, has attracted significant research interest. OVs have dual mechanisms of action: first, they selectively replicate within tumor cells and directly lyse them, producing the “oncolytic” effect (3); second, and more importantly, the viral replication and tumor cell lysis stimulate robust systemic anti-tumor immune responses in the host (4–8).
Newcastle disease virus (NDV) is an oncolytic virus known for its high safety profile. It primarily infects avian species and exhibits extremely low pathogenicity in humans, providing a strong basis for its clinical safety. In most tumor cells, the antiviral interferon signaling pathway is suppressed, allowing NDV to evade immune clearance and replicate extensively within these cells (9–12). In addition to directly lysing tumor cells, NDV activates the host’s innate and adaptive immune responses, demonstrating significant antitumor activity (13).
Several wild-type NDV strains, such as PV701 and 73-T, have entered clinical trials, demonstrating favorable safety profiles and antitumor efficacy. Although wild-type NDV inherently targets tumors and exhibits immunogenicity, its oncolytic effectiveness remains limited. This limitation primarily results from factors such as neutralization by pre-existing antibodies, insufficient replication efficiency, and impaired immune responses. The development of reverse genetics systems allows researchers to edit the NDV genome precisely, generating rNDV strains with significantly enhanced oncolytic efficacy. Current strategies primarily focus on modifying viral F or HN proteins to improve targeting, optimizing F protein cleavage sites to increase replication capacity within tumor cells, and utilizing NDV as a vector to express various exogenous genes. These recombinant viruses not only retain NDV’s inherent advantages but also exert localized effects within the TME through the expression of functional proteins, synergistically amplifying antitumor immune responses to ultimately achieve a “1 + 1>2” therapeutic effect.
Therefore, this article aims to provide a systematic review of research progress on rNDV in tumor therapy. By examining its modification strategies, mechanisms of action, preclinical and clinical research outcomes, and analyzing current challenges and future directions, it seeks to offer guidance for further research and clinical translation in this field.
2 Modification strategies for recombinant NDV
Genetic engineering has generated a new generation of highly effective and safe recombinant NDV by removing non-essential viral genes or inserting exogenous genes. This genetic modification primarily relies on reverse genetics techniques, which involve manipulating the viral genome at the DNA level, followed by rescuing viruses with specific characteristics. Genetic modification strategies for NDV include enhancing its targeting ability by modifying viral proteins, increasing its oncolytic capacity through the insertion of apoptosis-related genes or by antagonizing antiviral pathways in tumor cells, and promoting NDV’s antitumor immune response by incorporating immunomodulatory genes (Figure 1, Tables 1, 2).
Figure 1. Schematic diagram of NDV modification strategies. NDV, Newcastle disease virus; rNDV, recombinant Newcastle disease virus; NP, nucleoprotein; P, phosphoprotein; M, matrix protein; F, fusion protein; HN, hemagglutinin-neuraminidase; L, large protein. Created with Figdraw.
Table 1. Comparison of different modifying strategies.
Table 2. Modification of NDV.
2.1 Enhancing targeting capabilities
Although NDV exhibits tumor tropism, engineered modifications can further restrict its infection to specific tumor cell types, enabling precise targeting. This strategy involves genetically modifying viral surface proteins to increase infection efficiency in tumor cells while minimizing infection of healthy tissues.
The fusion (F) protein plays an important role in NDV-mediated cell fusion. Research indicates that mutating the DI-DII linker region of F protein alters its fusion activity, thereby promoting cell fusion independently of the hemagglutinin-neuraminidase (HN) protein (14). This HN-independent fusion capability offers novel opportunities for targeting tumor cells with NDV.
The HN protein primarily mediates the recognition of sialic acid receptors on cell surfaces. Modifying the HN protein can further enhance NDV’s tumor-targeting capabilities. Engineering specific regions of the HN protein can enhance its binding affinity to tumor cell surface receptors, thereby increasing viral infectivity. This strategy has been successfully applied in adenoviruses (15), providing strong support for analogous modifications in NDV.
Furthermore, nanotechnologies such as nanoparticles and nanocarriers can significantly enhance NDV’s targeting and delivery efficiency (16, 17). pH-sensitive surface protonation allows NDV to remain stable at physiological pH while rapidly increasing its affinity in the acidic TME, thereby effectively targeting tumor cells (18). This surface protonation-based affinity switching mechanism is more efficient than conventional charge-switching approaches.
2.2 Enhancing oncolytic efficacy
The oncolytic properties of NDV primarily result from defects in the antiviral interferon (IFN) signaling pathway within tumor cells and their diminished sensitivity to signaling mediated by the type I IFN receptors (9–11). Impaired antiviral IFN signaling allows viruses to replicate efficiently, leading to direct cell lysis. Despite this, some tumors retain the ability to mount effective antiviral responses, which may partially explain their resistance to oncolytic NDV therapy. Thus, repression of IFN induction during NDV infection may allow for better viral replication in tumors, suggesting that the oncolytic activity of NDV can be enhanced by improving the virus’s ability to suppress the antiviral immune response. Research indicates that the rNDV strain, which expresses the influenza non-structural protein 1 (NS1) known for its IFN-antagonist properties, reduces IFN expression by inhibiting retinoic acid-inducible gene I (RIG-I) receptor signaling, interferon regulatory factor 3 (IRF3) dimerization, and IFN-β production (19). This enhances the virus’s ability to form syncytia and lyse tumor cells (19). Another rNDV strain expressing an IFN-antagonistic protein also demonstrated enhanced oncolytic effects compared to wild-type NDV in a mouse fibrosarcoma model (20).
NDV can trigger immunogenic cell death (ICD), which can manifest through various pathways such as necrosis, necroptosis and pyroptosis (21–24). Genetic modification of NDV-induced apoptosis can further enhance its oncolytic efficacy. When the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene is inserted into the NDV genome, TRAIL binds to death receptors, significantly enhancing NDV’s therapeutic effect against malignant melanoma (25). The rNDV carrying the p53 gene (rNDV-p53) exhibits significant antitumor activity both in vitro and in vivo, inducing apoptosis in glioma cells by upregulating apoptosis-related genes (26). rNDV-B1/Fas, which expresses the human tumor necrosis factor receptor Fas, enhances both endogenous and exogenous apoptotic pathways, thereby amplifying NDV’s antitumor efficacy against melanoma (21).
2.3 Enhancing immunoregulatory functions
CD8+ T cells play a crucial role as effector cells in the immune response against tumors. Engineered NDV expressing cytokines or immune checkpoint inhibitors (ICIs) effectively enhances local immune cell infiltration and improves antitumor immune responses. Granulocyte-macrophage colony-stimulating factor (GM-CSF), which activates antigen-presenting cells (APCs), is commonly used to modify oncolytic viruses. T-VEC, a genetically modified herpes simplex virus that expresses GM-CSF, has been approved by the FDA for the treatment of metastatic melanoma (27). The recombinant NDV strain MEDI5395 expresses human GM-CSF and has been shown to enhance the secretion of pro-inflammatory cytokines in human peripheral blood mononuclear cells (PBMCs), including IFN-α, IL-6, IL-8, and tumor necrosis factor-alpha (TNF-α) (28). Cytokines are small proteins with diverse biological activities secreted by activated immune cells. They can directly stimulate immune effector cells within the tumor microenvironment or recruit additional immune cells to the tumor site, thereby enhancing the antitumor response of cytotoxic T cells (29). Multiple rNDVs expressing IFNs or pro-inflammatory cytokines have been developed, including rNDV-IL2 (30–33), rNDV-IL24 (34), and rNDV-IFN (35). In vitro and in vivo experiments demonstrate that these rNDVs exhibit stronger antitumor effects than wild-type strains (30–35). NDV-mip3a is a rNDV expressing macrophage inflammatory protein-3α (MIP-3α). This modification enhances antitumor activity by inducing a stronger systemic immune response and modulating the TME (36). Schirrmacher et al. engineered ATV-NDV to express bispecific anti−CD28 fusion protein (bsHN-CD28) on its surface, enabling it to bind directly to CD28 on T cells and deliver co-stimulatory signals (37). In a Phase I clinical trial, fourteen patients with advanced colorectal cancer treated with bsHN-CD28-modified ATV-NDV exhibited an immunological response characterized by tumor-reactive T cells, without any serious adverse events (37).
Dendritic cells (DCs) in the TME can be activated by oncolytic viruses through multiple mechanisms, including direct viral exposure and indirect activation via products released from infected neighboring tumor cells (38). DCs serve as critical targets for initial viral detection because their pattern recognition receptors (PRRs), including RIG-I-like receptors (RLRs) and toll-like receptors (TLRs), are activated upon sensing damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs). When stimulated by DAMPs and PAMPs, immature DCs upregulate the expression of major histocompatibility complex class I (MHC I) and class II (MHC II) molecules, as well as co-stimulatory molecules, leading to their maturation. These molecules facilitate the processing and presentation of antigens to naïve T cells, thereby inducing and expanding CD8+ T cell populations (39). Combining NDV with DCs enhances the antigen-presenting capacity of DCs, thereby promoting T-cell proliferation and cytokine secretion. A patient with hormone-refractory metastatic prostate cancer achieved complete remission following treatment with local hyperthermia (LHT) combined with viral oncolysate-pulsed dendritic cells (VOL-DCs) (40). This combination was shown to activate the immune system and induce a durable antitumor response. In another case report, a 70-year-old patient with invasive ductal breast cancer and liver metastases survived for more than 66 months following treatment with LHT and VOL-DCs, with no recurrence or additional metastases during this period (41).
Within the tumor microenvironment, regulatory T cells (Tregs) release inhibitory cytokines to suppress effector T cell, facilitating tumor evasion (42). Immune checkpoint inhibitors can block this effect. However, most patients do not respond to ICI therapy, primarily due to insufficient expression of target proteins in tumors or a lack of infiltrating cytotoxic T lymphocytes. On one hand, NDV induces the upregulation of immune checkpoints, including cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death-1 (PD-1). On the other hand, it triggers an inflammatory response that results in substantial infiltration of immune cells (43, 44). Consequently, combining OVs with ICIs can significantly enhance antitumor efficacy. The rNDV strains expressing checkpoint inhibitors (rNDV-anti-PD1 and rNDV-anti-PDL1) demonstrated enhanced antitumor effects when combined with CTLA-4 inhibitors, compared to the use of CTLA-4 inhibitors alone (45). NDV-ICOSL is a recombinant NDV expressing the inducible co-stimulator ligand (ICOSL), which increases the infiltration of activated T cells in both primary tumor sites and distant sites. When combined with CTLA-4 inhibitors, it significantly enhances the anti-tumor efficacy of immune checkpoint blockade therapies (46).
3 Anti-tumor mechanism of recombinant NDV
Recombinant NDV exhibits vastly enhanced antitumor potency. Its action transcends mere oncolysis, evolving into a multidimensional, synergistic process. The basis of rNDV’s attack on tumors is its direct oncolytic activity. This process begins with the specific binding of viral envelope proteins—such as the engineered, enhanced-targeting HN protein—to receptors on tumor cells. Subsequently, the virus enters the cell via membrane fusion or endocytosis, releasing viral ribonucleoprotein complexes (vRNPs) into the cytoplasm. The virus exploits the host cell’s transcriptional and translational machinery to synthesize substantial amounts of viral RNA and proteins, assembling them into new viral particles. Ultimately, the exocytosis and release of numerous viruses rupture the tumor cell membrane, leading to complete lysis and cell death. This process not only directly reduces tumor burden but, more importantly, induces immunogenic cell death, thereby laying the groundwork for subsequent activation of the immune system.
rNDV is capable of infecting normal cells within the tumor microenvironment, which have preserved type I IFN response. After rNDV infection, PAMPs inherent to the virus and DAMPs released by dying cancer cells are recognized by PRRs within immune cells. This activates a cascade of downstream signaling pathways involving nuclear factor kappa-B (NF-κB) and interferon regulatory factors (IRFs), leading to the rapid secretion of type I interferons and pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β (13). These cytokines recruit innate immune cells—including neutrophils, natural killer (NK) cells, and macrophages—to rapidly infiltrate the tumor. Concurrently, NK cells activated by cytokines such as IFNs directly kill tumor cells and secrete IFN-γ, further amplifying the immune response (66). High concentrations of inflammatory factors also suppress pre-existing immunosuppressive molecules within the TME, such as transforming growth factor-beta (TGF-β), and interfere with the immunosuppressive functions of Tregs and myeloid-derived suppressor cells (MDSCs). This process reprograms the TME, converting “cold” tumors into “hot” tumors and creating favorable conditions for initiating adaptive immune responses.
Inducing specific anti-tumor immunity is the primary mechanism through which rNDV exerts its long-lasting antitumor effects and prevents distant metastasis and recurrence. Upon lysis, tumor cells infected with rNDV release substantial quantities of DAMPs, such as calreticulin (CRT), ATP, and high-mobility group box 1 (HMGB1) (12). The uptake of these antigens triggers activation and maturation in cross-presenting DCs. Subsequently, activated DCs present processed antigen peptides via MHC-I and MHC-II molecules to naive CD8+ and CD4+ T cells, thereby activating and expanding large numbers of antigen-specific cytotoxic T lymphocytes (CTLs) and helper T (Th) cells. These activated T cells subsequently circulate through the bloodstream, infiltrate tumor tissues, and specifically recognize and eliminate tumor cells expressing the corresponding antigens via the perforin-granzyme pathway or the Fas/FasL pathway. The exogenous genes carried by rNDVs act as boosters in this process. GM-CSF enhances the recruitment and maturation of DCs and strengthens their antigen-presenting capabilities (28). IL-12 promotes the activation and proliferation of CTLs and NK cells (30–33). Meanwhile, immune checkpoint inhibitor single-chain variable fragments (scFv), such as anti-PD-L1, can relieve the suppression of infiltrating T cells by tumor cells (45), reversing T cell exhaustion and rendering the immune response more potent and enduring.
NDV selectively infects and lyses tumor vascular endothelial cells, playing a crucial role in tumor therapy (67). At the same time, it inhibits tumor angiogenesis by stimulating the production of TNF-α and IFN-γ (68). IFN-γ not only inhibits angiogenesis by downregulating the DLL4/Notch signaling pathway but also promotes vascular normalization through its interactions with endothelial cells, thereby enhancing antitumor immune responses (69, 70). Furthermore, TNF-α enhances immunotherapy efficacy by altering vascular endothelial barrier function and increasing T lymphocyte infiltration (71). These findings provide novel insights into NDV’s applications in tumor therapy and offer theoretical support for the development of inflammation-based antitumor strategies (72). A study demonstrates that VEGF-Trap-expressing rNDV reduces the growth rate of vascular endothelial cells by 85.37% (73). This rNDV exhibits an enhanced inhibition of colon cancer through amplified anti-angiogenesis.
The anti-tumor mechanism of rNDV involves an interconnected, stepwise, and synergistic process. NDV not only directly lyses cells but also induces innate and adaptive immune responses in the TME (Figure 2). This process is further enhanced by the expression of immunoregulatory genes, ultimately resulting in potent, long-lasting anti-tumor immunity.
Figure 2. The anti-tumor mechanism of rNDV. rNDV selectively infects and lyses tumor cells. Upon lysis, tumor cells release substantial quantities of DAMPs, PAMPs and TAAs. DAMPs are recognized by immune cells, leading to the secretion of pro-inflammatory cytokines. These cytokines recruit innate immune cells, including NK cells, neutrophils, and macrophages. Meanwhile, the uptake of antigens triggers the activation and maturation of APCs. APCs present antigens to naïve T cells, thereby activating them. Ultimately, activated CD8+ T cells specifically recognize and eliminate tumor cells that express the corresponding antigens. rNDV, recombinant Newcastle disease virus; DAMPs, damage-associated molecular patterns; PAMPs, pathogen-associated molecular patterns; TAAs, tumor-associated antigens; NK, natural killer; APC, antigen-presenting cell. Created with Figdraw.
4 Applications of recombinant NDV
Recombinant NDV has demonstrated therapeutic potential in multiple cancer types, including melanoma, primary hepatocellular carcinoma, colorectal cancer, breast cancer, and glioma. Recombinant NDV LX/IL (15 + 7), which co-expresses IL-7 and IL-15, enhanced the infiltration of CD8+ and CD4+ T cells, significantly inhibiting tumor growth in melanoma (59). rNDV-MIP3α induced cellular immune responses in melanoma, as demonstrated by a sevenfold increase in IFN-γ–secreting CD8+ T cells compared to the control group (36). Recombinant NDV with a modified F cleavage site prolonged survival in primary hepatocellular carcinoma, extending it to 35 days compared to 18 days in the control group (49). rNDV-IL12 suppressed the growth of colon cancer, resulting in a smaller tumor volume (537.90 ± 12.99 mm³) compared to that of the AF2240-i-treated group (1113.00 ± 32.16 mm³) (57). rNDV-IL12 modulated immune responses by increasing the levels of CD4+ T cells, CD8+ T cells, IL-2, IL-12, and IFN-γ (57). Recombinant NDV expressing IL-12 (rAF-IL12) resulted in 52% inhibition of breast cancer growth, whereas AF2240 caused 34.5% inhibition (74). Recombinant NDV expressing the human p53 gene has been shown to induce apoptosis in glioma cells, enhance cytotoxic T cell infiltration, and prolong survival in glioma-bearing mice (26). These studies provide evidence for the further application of rNDV in solid tumor therapy.
Clinical trials of NDV have demonstrated its efficacy and safety (Table 3). MEDI5395, a recombinant NDV expressing the human GM-CSF gene, demonstrated antitumor activity in Phase I clinical trials. When combined with durvalumab, it exhibited favorable safety and efficacy profiles in patients with advanced-stage tumors (75). NDV-GT, a recombinant NDV expressing porcine α1,3GT gene, induced surface expression of the αGal antigen on tumor cells. Pre-existing anti-αGal antibodies in the human body rapidly recognized this antigen, triggering a hyperacute immune rejection response that causes tumor vascular embolism and extensive tumor cell death. Results from a Phase I clinical trial reported in 2025 indicated that 90% of advanced cancer patients treated with NDV-GT achieved disease control without experiencing severe adverse effects (48). The clinical safety of NDV has been extensively demonstrated by data from multiple trials. No serious adverse events were reported in the clinical trials of NDV therapies. While current preclinical studies and preliminary clinical outcomes are encouraging, most rNDV therapies remain in preclinical or early clinical stages. Their safety, efficacy, and optimal application strategies require validation through further large-scale clinical trials.
Table 3. Clinical trials of NDV.
5 Combination strategies
Due to tumor heterogeneity, mutation burden, and variations in the TME, monotherapy-based tumor immunotherapy often leads to resistance, limiting the ability of OVs to achieve optimal antitumor efficacy. Combining OV therapy with other treatment modalities—such as chemotherapy, ICIs, adoptive cell therapy (ACT), and radiotherapy—may be essential for improving therapeutic outcomes.
The strategy of combining oncolytic viruses with chemotherapy remains a topic of controversy. Some clinical studies suggest that the combination of oncolytic viruses and chemotherapy can achieve satisfactory antitumor effects (86–90), but a large-scale clinical trial has produced conflicting results (91). Eigl et al. reported that metastatic prostate cancer patients treated with the oncolytic virus Pelareorep plus docetaxel had a median survival of 19.1 months, compared to 21.1 months for patients receiving docetaxel monotherapy (91). Another clinical trial found that Pelareorep combined with FOLFOX/Bevacizumab resulted in worse progression-free survival (PFS) compared to monotherapy (92). These conflicting results do not demonstrate the superiority of combining oncolytic viruses with chemotherapy over chemotherapy alone, suggesting that the combination may exhibit a “1 + 1 < 1” effect.
The combination of NDV with immunotherapy currently represents the most promising strategy. Possible reasons for the limited effectiveness of ICIs include a relatively low mutation burden, minimal T-cell infiltration, and an immunosuppressive TME. Studies have demonstrated that following NDV treatment, immune checkpoints such as CTLA-4 and PD-1 are significantly upregulated on infiltrating T cells in both the injected tumors and distant tumors (43, 44). Furthermore, the expression of programmed cell death ligand 1 (PD-L1) is increased in tumor cells, myeloid cells, and stromal cells following NDV infection (44). These findings suggest that combining NDV with ICIs may enhance antitumor efficacy (Figure 3). Co-administration of NDV with PD-1 or PD-L1 antibodies significantly improves the therapeutic response in melanoma, resulting in 90–100% tumor-free rates compared to 70% in the NDV monotherapy group (44). Another study demonstrates the superior efficacy of NDV combined with CTLA-4 antibodies compared to monotherapy in treating melanoma, colorectal cancer, and prostate cancer (43). Recombinant NDV expressing inducible co-stimulator ligand (NDV-ICOSL) increases infiltration of GrB+ICOS+CD8+ T cells. When combined with CTLA-4 antibodies, it demonstrated a 74% tumor-free rate in distant tumors, which was superior to the combination of wild-type NDV with anti-CTLA-4 (46). Although the combination strategy of rNDV and ICIs has shown promising results in preclinical studies, further prospective clinical trials are required to validate the efficacy.
Figure 3. The mechanism of combination therapy. The combination of oncolytic NDV and immune checkpoint inhibitors synergistically promotes the anti-tumor effect. NDV promotes the infiltration of CD8+ T cells and natural killer cells and upregulates the expression of PD-1 and PD-L1. Meanwhile, PD-1/PD-L1 inhibitors block the PD-1/PD-L1 pathway, thereby preventing tumor cells from evading the immune response. PD-1, programmed death-1; PD-L1/2, programmed death-ligand 1/2; TCR, T cell receptor; MHC I, major histocompatibility complex class I; NDV, Newcastle disease virus; Ab, antibody; NK, natural killer; Treg, regulatory T cell; MDSC, myeloid-derived suppressor cell. Created by Figdraw.
ACT has demonstrated significant efficacy in treating leukemia, melanoma, and lymphoma. However, its application to epithelial tumors is limited due to challenges related to cell infiltration and tumor heterogeneity (93). Combining OVs with ACT could potentially modify the TME of solid tumors, thereby overcoming current limitations. Chen et al. compared the efficacy of OV monotherapy with combination therapies involving chimeric antigen receptor T (CAR-T) cells and innate-like natural killer T (iNKT) cells. The results demonstrated the superiority of combination therapy over monotherapy (94). An oncolytic virus expressing truncated CD19 (CD19t) enhanced CAR-T cell targeting of solid tumors and further stimulated local antitumor immunity (95). On the other hand, CAR-T cells can serve as vectors for oncolytic viruses, delivering these viruses to tumor cells that express specific antigens. Delivering the myxoma virus to tumor cells expressing homologous antigens via CAR-T cells induces targeted tumor cell death and autophagy, resulting in tumor regression (96). These findings suggest that oncolytic viruses could be powerful tools to overcome limitations in adoptive cell therapy.
Other combination strategies include pairing with radiotherapy and targeted therapy. Results from a Phase I clinical trial of OPB301 combined with radiotherapy in esophageal cancer patients demonstrated an objective response rate (ORR) of 91.7% in 13 patients, with a favorable safety profile (97). The Phase III clinical trial of JX-594 combined with sorafenib for advanced hepatocellular carcinoma (NCT02562755) reported an ORR of only 19.2%, which was lower than the 20.9% observed in the sorafenib monotherapy group (98). Despite promising preclinical data suggesting that JX-594 could sensitize tumors to subsequent therapy with vascular endothelial growth factor (VEGF) inhibitors or vascular endothelial growth factor receptor (VEGFR) inhibitors, the trial results indicated that the combination did not demonstrate greater clinical benefit compared to sorafenib monotherapy (98, 99). Therefore, additional prospective clinical trials are necessary to validate the efficacy of NDV in combination with radiotherapy or targeted therapies.
6 Challenges and prospects
Compared to other oncolytic viruses, NDV has unique features: (1) NDV is a single-stranded negative-sense RNA virus that replicates in the cytoplasm, independently of the host cell's DNA replication machinery. It cannot integrate with the host genome. (2) While NDV replicates efficiently within tumors, it does not replicate in the normal cells of mammalian hosts. (3) NDV is cost-effective to produce, can be administered through various methods, and has minimal side effects.
NDV has demonstrated promising antitumor properties and a high safety profile in both preclinical and clinical studies. Despite its promising potential, studies of NDV therapy face significant challenges related to heterogeneity and methodological inconsistency, which complicate interpretation and hinder progress in the field. The primary issue is the profound heterogeneity of viral platforms and study designs across different investigations. Researchers have employed diverse reverse genetics systems, parental viral strains, and transgene payloads, which offer technical advantages during exploratory phases. However, this diversity has become a critical drawback—variations in viral backbones, production methods, and genetic modifications, making meaningful comparisons across trials nearly impossible. Moreover, early clinical trials frequently suffer from small sample sizes, single-arm designs, and a lack of standardized efficacy endpoints. Consequently, observed clinical outcomes are susceptible to confounding factors, preventing clear attribution to the oncolytic NDV itself. A third critical issue is the absence of reliable biomarker data to validate the NDV’s mechanism of action in patients. In most trials, it remains unclear whether limited efficacy results from the virus failing to infect and replicate within tumors, premature clearance by the host immune system, or an inability to overcome the immunosuppressive TME. The inconsistencies and limitations discussed above highlight the most urgent challenges currently facing the NDV field. Overcoming these hurdles is essential to translating preclinical promise into clinical reality. Therefore, future research must strategically focus on addressing the following key issues:
1. NDV is a persistent threat to the poultry industry.
2. The delivery of NDV should be optimized.
3. Complement and neutralizing antibodies compromise the therapeutic efficacy.
4. The side effects associated with NDV continue to warrant attention.
5. How to overcome the tumor heterogeneity is a problem that needs to be addressed.
6. Searching for biomarkers that can predict NDV’s efficacy is crucial.
Although NDV is of low pathogenicity in humans, it is highly contagious among poultry, which is a persistent threat to the poultry industry. The manufacture and use of NDV may result in its release into the environment, thereby necessitating regulatory oversight. Evaluating an oncolytic NDV for environmental safety is also important. However, there are few studies on the environmental shedding of NDV. Further research should be conducted and thoroughly documented.
Current delivery approaches include local delivery and systemic delivery. Most oncolytic virotherapies are administered through intratumoral injection. However, this method has specific drawbacks, including (1) Intratumoral injection may cause bleeding and unwanted metastasis at the lesion site. (2) Difficulties in accessing deep tumor tissues significantly limit the number of applicable cases. Thus, intravenous administration is essential for treating deep-seated or metastatic tumors. However, following intravenous injection, viral particles encounter multiple barriers. First, complement proteins and neutralizing antibodies in the bloodstream can neutralize and eliminate NDV before it reaches the tumor site. Second, the elevated pressure within the tumor stroma and the dense extracellular matrix hinders effective viral penetration and diffusion. Consequently, only a small fraction of the virus successfully reaches and infiltrates the tumor, thereby limiting its therapeutic efficacy. Altering the capsid, applying polymer coatings (100), or enhancing the extracellular envelope of NDVs can improve their shielding (101). Another effective strategy for intravenous injection involves encapsulating NDVs within cellular vectors or loading them onto these cells. Mesenchymal stem cells (MSCs) are promising candidates for delivering oncolytic viruses because they can transport viral particles, serve as factories for viral replication, and modulate the immune system (102–106).
NDV itself, as a foreign antigen, rapidly induces a strong antiviral immune response. Complement and neutralizing antibodies in the bloodstream can neutralize and eliminate NDV before it reaches the tumor site, severely compromising therapeutic efficacy. This may render subsequent doses ineffective, hindering the implementation of repeated, multi-course intensive therapy. Overcoming or circumventing host innate immunity represents the primary challenge in enhancing NDV efficacy. Employing cellular vector systems for NDV delivery represents a highly promising strategy. Cells such as mesenchymal stem cells (MSCs), cytokine-induced killer cells (CIK), or CD8+ T cells, which exhibit natural chemotaxis towards tumors, can serve as viral carriers. These cells carry and protect the virus, effectively evading neutralizing antibodies and complement attacks until reaching the tumor, where they release progeny viruses, achieving tumor-targeted delivery and efficient infection.
Regarding safety, the most frequently reported side effects in OV clinical trials include fever, fatigue, nausea, flu-like symptoms, and pain at the injection site. There is an overall incidence of adverse events of 26.6% associated with OV therapy (107). Compared to other immunotherapy products, OV has a more favorable safety profile. However, due to the heterogeneity both between and within tumors, the absence of specific receptors or promoters in tumor cells may lead to off-target effects, resulting in immune-related adverse events (108). The risks increase significantly when NDV is used in combination with immune checkpoint inhibitors or is modified to express immune modulators (109, 110). Cytokine release syndrome (CRS), a serious adverse effect, can also be triggered by OV therapy (111–113). Essential strategies to minimize side effects include enhancing tumor targeting through genetic engineering, dosing guided by pharmacokinetic principles, intratumoral administration to reduce systemic toxicity, and a low-dose fractionated schedule optimized for efficacy (114–116).
Cancer cells exhibit high heterogeneity in receptor expression, integrity of interferon pathways, and proliferative states. One the one hand, NDV infection requires attachment to cell surface receptors, primarily sialic acid-containing glycoproteins. There is considerable variability in the expression levels of these receptors both between different types of cancer and among patients with the same type of cancer. The absence or low expression of receptors in tumors renders them resistant to infection, posing a significant barrier to oncolysis. On the other hand, most cancer cells have defects in their IFN signaling pathways, which allows NDVs to replicate efficiently within them. However, the impairment is typically not absolute. Cancer cells with an intact IFN pathway can mount an effective antiviral response, clearing the virus and resulting in treatment resistance. In addition, the highly immunosuppressed TME lacks T-cell infiltration. Even when NDV lyses tumor cells and releases antigens, it fails to effectively initiate specific anti-tumor immune responses, thus limiting therapeutic efficacy. Hence, developing strategies that combine therapies for synergistic effects is a major research objective. Chemotherapy and radiotherapy can induce ICD, further promoting tumor antigen release and complementing NDV’s immune-activating effects. Combination with immune checkpoint inhibitors can relieve T-cell suppression, facilitating the successful removal of PD-L1-positive tumor cell subpopulations. This synergy addresses tumor heterogeneity.
Biomarkers play a crucial role in advancing individualized precision oncology by enabling clinicians to provide care that is more effective, less toxic, and more cost-efficient. However, research on biomarkers for oncolytic viruses remains limited. It is necessary to search for biomarkers that can predict the efficacy of NDV, such as pre-existing antibody titers, tumor viral receptor expression levels, IFN signaling pathway status, immune cell infiltration, post-treatment viral replication in peripheral blood, and cytokine dynamics. This will enable the identification of populations likely to benefit, facilitate real-time efficacy monitoring, and allow timely adjustment of treatment strategies.
In summary, this review has outlined the modification strategies, antitumor mechanisms, clinical translation, combination strategies, and challenges of rNDV immunotherapy. Table 4 provides a quick reference summary of all that this review entails.
Table 4. Advancements in recombinant NDV for cancer therapy.
7 Conclusion
In conclusion, advancements in genetic engineering technology have enabled the enhancement of NDV’s targeting potential through the modification of viral proteins, as well as the improvement of its immune-stimulating capabilities by inserting exogenous genes. However, numerous unresolved challenges remain in NDV-based cancer therapy, including determining the most effective delivery route, developing strategies to evade neutralizing antibodies, overcoming tumor heterogeneity, and identifying relevant biomarkers. Future research priorities will focus on four key areas: the rational design of a new generation of rNDVs armed with potent immunomodulatory transgenes; the use of cellular vehicles for targeted delivery; the development of bispecific NDVs capable of redirecting immune effector cells; and the creation of synergistic therapeutic regimens that combine NDV with immune checkpoint inhibitors.
Author contributions
JS: Writing – original draft, Writing – review & editing, Conceptualization. JW: Writing – review & editing. MX: Writing – review & editing. LC: Conceptualization, Writing – review & editing, Supervision. YG: Writing – review & editing, Supervision.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This study was supported by Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project (2025ZD01903703) and Wu Jieping Medical Foundation (320.6750.2023-05-12).
Conflict of interest
The authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Jiang Y, Zhao X, Fu J, and Wang H. Progress and challenges in precise treatment of tumors with PD-1/PD-L1 blockade. Front Immunol. (2020) 11:339. doi: 10.3389/fimmu.2020.00339
2. Da L, Teng Y, Wang N, Zaguirre K, Liu Y, Qi Y, et al. Organ-specific immune-related adverse events associated with immune checkpoint inhibitor monotherapy versus combination therapy in cancer: A meta-analysis of randomized controlled trials. Front Pharmacol. (2019) 10:1671. doi: 10.3389/fphar.2019.01671
3. Gujar S, Bell J, and Diallo JS. SnapShot: cancer immunotherapy with oncolytic viruses. Cell. (2019) 176:1240–.e1. doi: 10.1016/j.cell.2019.01.051
4. Hou W, Sampath P, Rojas JJ, and Thorne SH. Oncolytic virus-mediated targeting of PGE2 in the tumor alters the immune status and sensitizes established and resistant tumors to immunotherapy. Cancer Cell. (2016) 30:108–19. doi: 10.1016/j.ccell.2016.05.012
5. Gujar S, Pol JG, and Kroemer G. Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies. Oncoimmunology. (2018) 7:e1442169. doi: 10.1080/2162402X.2018.1442169
6. Gujar SA and Lee PW. Oncolytic virus-mediated reversal of impaired tumor antigen presentation. Front Oncol. (2014) 4:77. doi: 10.3389/fonc.2014.00077
7. Delaunay T, Violland M, Boisgerault N, Dutoit S, Vignard V, Münz C, et al. Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells. Oncoimmunology. (2018) 7:e1407897. doi: 10.1080/2162402X.2017.1407897
8. Kanaya N, Kuroda S, Kakiuchi Y, Kumon K, Tsumura T, Hashimoto M, et al. Immune modulation by telomerase-specific oncolytic adenovirus synergistically enhances antitumor efficacy with anti-PD1 antibody. Mol Ther. (2020) 28:794–804. doi: 10.1016/j.ymthe.2020.01.003
9. Zamarin D and Palese P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol. (2012) 7:347–67. doi: 10.2217/fmb.12.4
10. Fiola C, Peeters B, Fournier P, Arnold A, Bucur M, and Schirrmacher V. Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J cancer. (2006) 119:328–38. doi: 10.1002/ijc.21821
11. Krishnamurthy S, Takimoto T, Scroggs RA, and Portner A. Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J virology. (2006) 80:5145–55. doi: 10.1128/JVI.02618-05
12. Burman B, Pesci G, and Zamarin D. Newcastle disease virus at the forefront of cancer immunotherapy. Cancers. (2020) 12:3552. doi: 10.3390/cancers12123552
13. Kowalinski E, Lunardi T, McCarthy AA, Louber J, Brunel J, Grigorov B, et al. Structural basis for the activation of innate immune pattern-recognition receptor RIG-I by viral RNA. Cell. (2011) 147:423–35. doi: 10.1016/j.cell.2011.09.039
14. Chi M, Xie W, Liu Y, Wen H, Zhao L, Song Y, et al. Mutations in the DI-DII linker of the NDV fusion protein conferred hemagglutinin-neuraminidase-independent cell fusion promotion. J Gen virology. (2019) 100:958–67. doi: 10.1099/jgv.0.001278
15. Wienen F, Nilson R, Allmendinger E, Peters S, Barth TFE, Kochanek S, et al. An oncolytic HAdV-5 with reduced surface charge combines diminished toxicity and improved tumor targeting. Mol Ther Oncol. (2024) 32:200909. doi: 10.1016/j.omton.2024.200909
16. Tian M, Liu X, and Pei H. Nanomaterial-based cancer immunotherapy: enhancing treatment strategies. Front Chem. (2024) 12:1492215. doi: 10.3389/fchem.2024.1492215
17. Lin Y, Lin P, Xu R, Chen X, Lu Y, Zheng J, et al. Nanovaccines empowering CD8(+) T cells: a precision strategy to enhance cancer immunotherapy. Theranostics. (2025) 15:3098–121. doi: 10.7150/thno.107856
18. Wang Z, Ma G, Zhang J, Yuan Z, Wang L, Bernards M, et al. Surface protonation/deprotonation controlled instant affinity switch of nano drug vehicle (NDV) for pH triggered tumor cell targeting. Biomaterials. (2015) 62:116–27. doi: 10.1016/j.biomaterials.2015.05.020
19. Zamarin D, Martínez-Sobrido L, Kelly K, Mansour M, Sheng G, Vigil A, et al. Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther. (2009) 17:697–706. doi: 10.1038/mt.2008.286
20. Elankumaran S, Chavan V, Qiao D, Shobana R, Moorkanat G, Biswas M, et al. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy. J virology. (2010) 84:3835–44. doi: 10.1128/JVI.01553-09
21. Cuadrado-Castano S, Ayllon J, Mansour M, de la Iglesia-Vicente J, Jordan S, Tripathi S, et al. Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models. Mol Cancer Ther. (2015) 14:1247–58. doi: 10.1158/1535-7163.MCT-14-0913
22. Cheng JH, Sun YJ, Zhang FQ, Zhang XR, Qiu XS, Yu LP, et al. Newcastle disease virus NP and P proteins induce autophagy via the endoplasmic reticulum stress-related unfolded protein response. Sci Rep. (2016) 6:24721. doi: 10.1038/srep24721
23. Ye T, Jiang K, Wei L, Barr MP, Xu Q, Zhang G, et al. Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells. Am J Cancer Res. (2018) 8:1514–27.
24. Kroemer G, Galluzzi L, Kepp O, and Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. (2013) 31:51–72. doi: 10.1146/annurev-immunol-032712-100008
25. Bai FL, Tian H, Yu YH, Yin JC, Ren GP, Zhou B, et al. TNF-related apoptosis-inducing ligand delivered by rNDV is a novel agent for cancer gene therapy. Technol Cancer Res Treat. (2015) 14:737–46. doi: 10.7785/tcrt.2012.500446
26. Fan X, Lu H, Cui Y, Hou X, Huang C, and Liu G. Overexpression of p53 delivered using recombinant NDV induces apoptosis in glioma cells by regulating the apoptotic signaling pathway. Exp Ther Med. (2018) 15:4522–30. doi: 10.3892/etm.2018.5935
27. Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. (2018) 36:1658–67. doi: 10.1200/JCO.2017.73.7379
28. Burke S, Shergold A, Elder MJ, Whitworth J, Cheng X, Jin H, et al. Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro. Cancer immunology immunotherapy: CII. (2020) 69:1015–27. doi: 10.1007/s00262-020-02495-x
29. Lee S and Margolin K. Cytokines in cancer immunotherapy. Cancers. (2011) 3:3856–93. doi: 10.3390/cancers3043856
30. Vigil A, Park MS, Martinez O, Chua MA, Xiao S, Cros JF, et al. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. (2007) 67:8285–92. doi: 10.1158/0008-5472.CAN-07-1025
31. Wu Y, He J, An Y, Wang X, Liu Y, Yan S, et al. Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy. J Pharmacol Sci. (2016) 132:24–30. doi: 10.1016/j.jphs.2016.03.012
32. Ren G, Tian G, Liu Y, He J, Gao X, Yu Y, et al. Recombinant newcastle disease virus encoding IL-12 and/or IL-2 as potential candidate for hepatoma carcinoma therapy. Technol Cancer Res Treat. (2016) 15:Np83–94. doi: 10.1177/1533034615601521
33. Bai FL, Yu YH, Tian H, Ren GP, Wang H, Zhou B, et al. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy. Cancer Biol Ther. (2014) 15:1226–38. doi: 10.4161/cbt.29686
34. Xu X, Yi C, Yang X, Xu J, Sun Q, Liu Y, et al. Tumor cells modified with newcastle disease virus expressing IL-24 as a cancer vaccine. Mol Ther oncolytics. (2019) 14:213–21. doi: 10.1016/j.omto.2019.06.001
35. Buijs P, van Nieuwkoop S, Vaes V, Fouchier R, van Eijck C, and van den Hoogen B. Recombinant immunomodulating lentogenic or mesogenic oncolytic newcastle disease virus for treatment of pancreatic adenocarcinoma. Viruses. (2015) 7:2980–98. doi: 10.3390/v7062756
36. Huang FY, Wang JY, Dai SZ, Lin YY, Sun Y, Zhang L, et al. A recombinant oncolytic Newcastle virus expressing MIP-3α promotes systemic antitumor immunity. J immunotherapy cancer. (2020) 8:e000330. doi: 10.1136/jitc-2019-000330
37. Schirrmacher V, Schlude C, Weitz J, and Beckhove P. Strong T−cell costimulation can reactivate tumor antigen−specific T cells in late−stage metastasized colorectal carcinoma patients: results from a phase I clinical study. Int J Oncol. (2015) 46:71–7. doi: 10.3892/ijo.2014.2692
38. Marelli G, Howells A, Lemoine NR, and Wang Y. Oncolytic viral therapy and the immune system: A double-edged sword against cancer. Front Immunol. (2018) 9:866. doi: 10.3389/fimmu.2018.00866
39. Xu Q, Rangaswamy US, Wang W, Robbins SH, Harper J, Jin H, et al. Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo. Int J cancer. (2020) 146:531–41. doi: 10.1002/ijc.32694
40. Schirrmacher V, Bihari AS, Stücker W, and Sprenger T. Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report. Oncol letters. (2014) 8:2403–6. doi: 10.3892/ol.2014.2588
41. Schirrmacher V, Stücker W, Lulei M, Bihari AS, and Sprenger T. Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report. Immunotherapy. (2015) 7:855–60. doi: 10.2217/imt.15.48
42. Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, et al. Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion. Nat Immunol. (2019) 20:724–35. doi: 10.1038/s41590-019-0346-9
43. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Trans Med. (2014) 6:226ra32. doi: 10.1126/scitranslmed.3008095
44. Zamarin D, Ricca JM, Sadekova S, Oseledchyk A, Yu Y, Blumenschein WM, et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J Clin Invest. (2018) 128:1413–28. doi: 10.1172/JCI98047
45. Vijayakumar G, McCroskery S, and Palese P. Engineering newcastle disease virus as an oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines. J virology. (2020) 94:e01677–19. doi: 10.1128/JVI.01677-19
46. Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P, et al. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun. (2017) 8:14340. doi: 10.1038/ncomms14340
47. Wu Y, He J, Geng J, An Y, Ye X, Yan S, et al. Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy. Eur J Pharmacol. (2017) 802:85–92. doi: 10.1016/j.ejphar.2017.02.042
48. Zhong L, Gan L, Wang B, Wu T, Yao F, Gong W, et al. Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients. Cell. (2025) 188:1119–36.e23. doi: 10.1016/j.cell.2024.12.010
49. Altomonte J, Marozin S, Schmid RM, and Ebert O. Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther. (2010) 18:275–84. doi: 10.1038/mt.2009.231
50. Li Z, Qian W, Zhang Y, Liao C, Chen J, Ding K, et al. Enhanced oncolytic potential of engineered newcastle disease virus lasota strain through modification of its F protein cleavage site. Microorganisms. (2024) 12:2029. doi: 10.3390/microorganisms12102029
51. Jung BK, An YH, Jang SH, Jang JJ, Kim S, Jeon JH, et al. The artificial amino acid change in the sialic acid-binding domain of the hemagglutinin neuraminidase of newcastle disease virus increases its specificity to HCT 116 colorectal cancer cells and tumor suppression effect. Virol J. (2024) 21:7. doi: 10.1186/s12985-023-02276-9
52. Bu X, Li M, Zhao Y, Liu S, Wang M, Ge J, et al. Genetically engineered Newcastle disease virus expressing human interferon-λ1 induces apoptosis in gastric adenocarcinoma cells and modulates the Th1/Th2 immune response. Oncol Rep. (2016) 36:1393–402. doi: 10.3892/or.2016.4925
53. Jung BK, An YH, Jang SH, Ryu G, Jung SB, Kim S, et al. The tumor suppressive effect and apoptotic mechanism of TRAIL gene-containing recombinant NDV in TRAIL-resistant colorectal cancer HT-29 cells and TRAIL-nonresistant HCT116 cells, with each cell bearing a mouse model. Cancer Med. (2023) 12:20380–95. doi: 10.1002/cam4.6622
54. Cheng X, Wang W, Xu Q, Harper J, Carroll D, Galinski MS, et al. Genetic modification of oncolytic newcastle disease virus for cancer therapy. J virology. (2016) 90:5343–52. doi: 10.1128/JVI.00136-16
55. Harper J, Burke S, Travers J, Rath N, Leinster A, Navarro C, et al. Recombinant newcastle disease virus immunotherapy drives oncolytic effects and durable systemic antitumor immunity. Mol Cancer Ther. (2021) 20:1723–34. doi: 10.1158/1535-7163.MCT-20-0902
56. Zhao L, Mei Y, Sun Q, Guo L, Wu Y, Yu X, et al. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response. J Immunol (Baltimore Md: 1950). (2014) 193:735–45. doi: 10.4049/jimmunol.1400004
57. Najmuddin S, Amin ZM, Tan SW, Yeap SK, Kalyanasundram J, Ani MAC, et al. Cytotoxicity study of the interleukin-12-expressing recombinant Newcastle disease virus strain, rAF-IL12, towards CT26 colon cancer cells in vitro and in vivo. Cancer Cell Int. (2020) 20:278. doi: 10.1186/s12935-020-01372-y
58. Bai F, Niu Z, Tian H, Li S, Lv Z, Zhang T, et al. Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy. Immunol Lett. (2014) 159:36–46. doi: 10.1016/j.imlet.2014.02.009
59. Xu X, Sun Q, Mei Y, Liu Y, and Zhao L. Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy. Cancer science. (2018) 109:279–88. doi: 10.1111/cas.13468
60. Wu Q, Jin Y, Li S, Guo X, Sun W, Liu J, et al. Oncolytic Newcastle disease virus carrying the IL24 gene exerts antitumor effects by inhibiting tumor growth and vascular sprouting. Int immunopharmacology. (2024) 136:112305. doi: 10.1016/j.intimp.2024.112305
61. Tian L, Liu T, Jiang S, Cao Y, Kang K, Su H, et al. Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy. Gene Ther. (2023) 30:64–74. doi: 10.1038/s41434-021-00256-8
62. Jang SH, Jung BK, An YH, and Jang H. The phosphatase and tensin homolog gene inserted between NP and P gene of recombinant New castle disease virus oncolytic effect test to glioblastoma cell and xenograft mouse model. Virol J. (2022) 19:21. doi: 10.1186/s12985-022-01746-w
63. Vigil A, Martinez O, Chua MA, and García-Sastre A. Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol Ther. (2008) 16:1883–90. doi: 10.1038/mt.2008.181
64. Liu L, Song L, Liu T, Hui K, Hu C, Yang J, et al. Recombinant oncolytic virus NDV-anti-VEGFR2 enhances radiotherapy sensitivity in NSCLC by targeting VEGF signaling and impairing DNA repair. Gene Ther. (2025) 32:517–28. doi: 10.1038/s41434-025-00540-x
65. Santry LA, van Vloten JP, AuYeung AWK, Mould RC, Yates JGE, McAusland TM, et al. Recombinant Newcastle disease viruses expressing immunological checkpoint inhibitors induce a pro-inflammatory state and enhance tumor-specific immune responses in two murine models of cancer. Front Microbiol. (2024) 15:1325558. doi: 10.3389/fmicb.2024.1325558
66. Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res. (2007) 13:6419–28. doi: 10.1158/1078-0432.CCR-07-0865
67. Fournier P, Arnold A, Wilden H, and Schirrmacher V. Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. Int J Oncol. (2012) 40:840–50. doi: 10.3892/ijo.2011.1265
68. Zhao L, Niu C, Shi X, Xu D, Li M, Cui J, et al. Dendritic cells loaded with the lysate of tumor cells infected with Newcastle Disease Virus trigger potent anti-tumor immunity by promoting the secretion of IFN-γ and IL-2 from T cells. Oncol letters. (2018) 16:1180–8. doi: 10.3892/ol.2018.8785
69. Deng J, Liu X, Rong L, Ni C, Li X, Yang W, et al. IFNγ-responsiveness of endothelial cells leads to efficient angiostasis in tumours involving down-regulation of Dll4. J pathology. (2014) 233:170–82. doi: 10.1002/path.4340
70. Cai Z, Meng K, Yu T, Xi Y, Yuan Z, Wang X, et al. IFN-γ-mediated suppression of ANGPT2-Tie2 in endothelial cells facilitates tumor vascular normalization during immunotherapy. Front Immunol. (2025) 16:1551322. doi: 10.3389/fimmu.2025.1551322
71. Calcinotto A, Grioni M, Jachetti E, Curnis F, Mondino A, Parmiani G, et al. Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J Immunol (Baltimore Md: 1950). (2012) 188:2687–94. doi: 10.4049/jimmunol.1101877
72. Uldry E, Faes S, Demartines N, and Dormond O. Fine-tuning tumor endothelial cells to selectively kill cancer. Int J Mol Sci. (2017) 18:1401. doi: 10.3390/ijms18071401
73. Meng F, Cao Y, Su H, Liu T, Tian L, Zhang Y, et al. Newcastle disease virus expressing an angiogenic inhibitor exerts an enhanced therapeutic efficacy in colon cancer model. PloS One. (2022) 17:e0264896. doi: 10.1371/journal.pone.0264896
74. Mohamed Amin Z, Che Ani MA, Tan SW, Yeap SK, Alitheen NB, Syed Najmuddin SUF, et al. Evaluation of a recombinant newcastle disease virus expressing human IL12 against human breast cancer. Sci Rep. (2019) 9:13999. doi: 10.1038/s41598-019-50222-z
75. Davar D, Carneiro BA, Dy GK, Sheth S, Borad MJ, Harrington KJ, et al. Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors. J immunotherapy cancer. (2024) 12:e009336. doi: 10.1136/jitc-2024-009336
76. Cassel WA and Murray DR. A ten-year follow-up on stage II Malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol tumor pharmacotherapy. (1992) 9:169–71. doi: 10.1007/BF02987752
77. Batliwalla FM, Bateman BA, Serrano D, Murray D, Macphail S, Maino VC, et al. A 15-year follow-up of AJCC stage III Malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med (Cambridge Mass). (1998) 4:783–94. doi: 10.1007/BF03401771
78. Csatary LK, Eckhardt S, Bukosza I, Czegledi F, Fenyvesi C, Gergely P, et al. Attenuated veterinary virus vaccine for the treatment of cancer. Cancer detection Prev. (1993) 17:619–27.
79. Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther. (2006) 13:221–8. doi: 10.1016/j.ymthe.2005.08.016
80. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol. (2002) 20:2251–66. doi: 10.1200/JCO.2002.08.042
81. Laurie SA, Bell JC, Atkins HL, Roach J, Bamat MK, O’Neil JD, et al. A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res. (2006) 12:2555–62. doi: 10.1158/1078-0432.CCR-05-2038
82. Lorence RM, Roberts MS, O’Neil JD, Groene WS, Miller JA, Mueller SN, et al. Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr Cancer Drug targets. (2007) 7:157–67. doi: 10.2174/156800907780058853
83. Hotte SJ, Lorence RM, Hirte HW, Polawski SR, Bamat MK, O’Neil JD, et al. An optimized clinical regimen for the oncolytic virus PV701. Clin Cancer Res. (2007) 13:977–85. doi: 10.1158/1078-0432.CCR-06-1817
84. Karcher J, Dyckhoff G, Beckhove P, Reisser C, Brysch M, Ziouta Y, et al. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res. (2004) 64:8057–61. doi: 10.1158/0008-5472.CAN-04-1545
85. Steiner HH, Bonsanto MM, Beckhove P, Brysch M, Geletneky K, Ahmadi R, et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol. (2004) 22:4272–81. doi: 10.1200/JCO.2004.09.038
86. Garcia-Carbonero R, Bazan-Peregrino M, Gil-Martín M, Álvarez R, Macarulla T, Riesco-Martinez MC, et al. multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors. J immunotherapy cancer. (2022) 10:e003255. doi: 10.1136/jitc-2021-003255
87. Bernstein V, Ellard SL, Dent SF, Tu D, Mates M, Dhesy-Thind SK, et al. A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. Breast Cancer Res Treat. (2018) 167:485–93. doi: 10.1007/s10549-017-4538-4
88. Lee JC, Shin DW, Park H, Kim J, Youn Y, Kim JH, et al. Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 trial. Gastrointestinal endoscopy. (2020) 92:1044–52.e1. doi: 10.1016/j.gie.2020.02.012
89. Mahalingam D, Goel S, Aparo S, Patel Arora S, Noronha N, Tran H, et al. A phase II study of pelareorep (REOLYSIN(®)) in combination with gemcitabine for patients with advanced pancreatic adenocarcinoma. Cancers. (2018) 10:160. doi: 10.3390/cancers10060160
90. Moreno V, Barretina-Ginesta MP, García-Donas J, Jayson GC, Roxburgh P, Vázquez RM, et al. Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial. J immunotherapy cancer. (2021) 9:e003645. doi: 10.1136/jitc-2021-003645
91. Eigl BJ, Chi K, Tu D, Hotte SJ, Winquist E, Booth CM, et al. A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209. Oncotarget. (2018) 9:8155–64. doi: 10.18632/oncotarget.24263
92. Jonker DJ, Tang PA, Kennecke H, Welch SA, Cripps MC, Asmis T, et al. A randomized phase II study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND.210, a canadian cancer trials group trial. Clin colorectal Cancer. (2018) 17:231–9.e7. doi: 10.1016/j.clcc.2018.03.001
93. Twumasi-Boateng K, Pettigrew JL, Kwok YYE, Bell JC, and Nelson BH. Oncolytic viruses as engineering platforms for combination immunotherapy. Nat Rev Cancer. (2018) 18:419–32. doi: 10.1038/s41568-018-0009-4
94. Chen T, Ding X, Liao Q, Gao N, Chen Y, Zhao C, et al. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy. J immunotherapy cancer. (2021) 9:e001647. doi: 10.1136/jitc-2020-001647
95. Park AK, Fong Y, Kim SI, Yang J, Murad JP, Lu J, et al. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Sci Trans Med. (2020) 12:eaaz1863. doi: 10.1126/scitranslmed.aaz1863
96. Zheng N, Fang J, Xue G, Wang Z, Li X, Zhou M, et al. Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance. Cancer Cell. (2022) 40:973–85.e7. doi: 10.1016/j.ccell.2022.08.001
97. Shirakawa Y, Tazawa H, Tanabe S, Kanaya N, Noma K, Koujima T, et al. Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments. Eur J Cancer (Oxford England: 1990). (2021) 153:98–108. doi: 10.1016/j.ejca.2021.04.043
98. Abou-Alfa GK, Galle PR, Chao Y, Erinjeri J, Heo J, Borad MJ, et al. PHOCUS: A phase 3, randomized, open-label study of sequential treatment with pexa-vec (JX-594) and sorafenib in patients with advanced hepatocellular carcinoma. Liver cancer. (2024) 13:248–64. doi: 10.1159/000533650
99. Heo J, Breitbach CJ, Moon A, Kim CW, Patt R, Kim MK, et al. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol therapy: J Am Soc Gene Ther. (2011) 19:1170–9. doi: 10.1038/mt.2011.39
100. Sun Y, Lv X, Ding P, Wang L, Sun Y, Li S, et al. Exploring the functions of polymers in adenovirus-mediated gene delivery: Evading immune response and redirecting tropism. Acta biomaterialia. (2019) 97:93–104. doi: 10.1016/j.actbio.2019.06.059
101. Kirn DH, Wang Y, Liang W, Contag CH, and Thorne SH. Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res. (2008) 68:2071–5. doi: 10.1158/0008-5472.CAN-07-6515
102. Du W, Seah I, Bougazzoul O, Choi G, Meeth K, Bosenberg MW, et al. Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. Proc Natl Acad Sci United States America. (2017) 114:E6157–e65. doi: 10.1073/pnas.1700363114
103. Moreno R. Mesenchymal stem cells and oncolytic viruses: joining forces against cancer. J immunotherapy cancer. (2021) 9:e001684. doi: 10.1136/jitc-2020-001684
104. Ramírez M, García-Castro J, Melen GJ, González-Murillo Á, and Franco-Luzón L. Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technology. Oncolytic virotherapy. (2015) 4:149–55. doi: 10.2147/OV.S66010
105. Xia X, Ji T, Chen P, Li X, Fang Y, Gao Q, et al. Mesenchymal stem cells as carriers and amplifiers in CRAd delivery to tumors. Mol cancer. (2011) 10:134. doi: 10.1186/1476-4598-10-134
106. Yong RL, Shinojima N, Fueyo J, Gumin J, Vecil GG, Marini FC, et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res. (2009) 69:8932–40. doi: 10.1158/0008-5472.CAN-08-3873
107. Lau P, Liang L, Chen X, Zhang J, and Liu H. Comparative safety and efficacy of oncolytic virotherapy for the treatment of individuals with Malignancies: a systematic review, meta-analysis, and Bayesian network meta-analysis. EClinicalMedicine. (2025) 86:103362. doi: 10.1016/j.eclinm.2025.103362
108. Xu J, Xia Z, Wang S, and Xia Q. Resistance to oncolytic virotherapy: Multidimensional mechanisms and therapeutic breakthroughs (Review). Int J Mol Med. (2025) 56:171. doi: 10.3892/ijmm.2025.5612
109. Azar F, Deforges J, Demeusoit C, Kleinpeter P, Remy C, Silvestre N, et al. TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment. J immunotherapy cancer. (2024) 12:e009302. doi: 10.1136/jitc-2024-009302
110. Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, et al. Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J Clin Oncol. (2023) 41:528–40. doi: 10.1200/JCO.22.00343
111. Dong S, Liu B, Hu S, Guo F, Zhong Y, Cai Q, et al. A novel oncolytic virus induces a regional cytokine storm and safely eliminates Malignant ascites of colon cancer. Cancer Med. (2022) 11:4297–309. doi: 10.1002/cam4.4772
112. Morris EC, Neelapu SS, Giavridis T, and Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. (2022) 22:85–96. doi: 10.1038/s41577-021-00547-6
113. Shah D, Soper B, and Shopland L. Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures. Front Immunol. (2023) 14:1190379. doi: 10.3389/fimmu.2023.1190379
114. Cyrelle Ornella MS, Kim JJ, Cho E, Cho M, and Hwang TH. Dose considerations for vaccinia oncolytic virus based on retrospective reanalysis of early and late clinical trials. Vaccines. (2024) 12:1010. doi: 10.3390/vaccines12091010
115. Gu X, Zhang Y, Zhou W, Wang F, Yan F, Gao H, et al. Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers. Exp Hematol Oncol. (2024) 13:70. doi: 10.1186/s40164-024-00542-2
Keywords: cancer treatment, gene editing, immunotherapy, Newcastle disease virus, oncolytic virotherapy
Citation: Sun J, Wang J, Xiao M, Chen L and Guan Y (2025) Research progress on recombinant NDV in cancer therapy. Front. Immunol. 16:1735440. doi: 10.3389/fimmu.2025.1735440
Received: 30 October 2025; Accepted: 02 December 2025; Revised: 02 December 2025;
Published: 17 December 2025.
Edited by:
Zong Sheng Guo, University at Buffalo, United StatesReviewed by:
Richard Kolade Omole, Osun State University, NigeriaSeyedeh Nasim Mirbahari, Royan institute for Stem Cell Biology and Technology (RI-SCBT), Iran
Ekaterina Minskaia, Sirius University, Russia
Copyright © 2025 Sun, Wang, Xiao, Chen and Guan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yi Guan, eWd1YW5AaGt1Lmhr; Liming Chen, YW5nZWxjaGVuMDhAc2luYS5jb20=